We read with interest the article by Choi et al entitled ''Assessment of Arterial Stiffness in Korean Patients With Psoriasis by Cardio-Ankle Vascular Index.'' 1 They found that psoriasis is an independent predictor of arterial stiffness. 2 Psoriasis is a chronic, immune-mediated, inflammatory skin disease with a prevalence of 2% to 3% in Europeans. 3 Inflammation is associated with impaired insulin sensitivity, carotid intima-media thickening, endothelial dysfunction, and aortic stiffness, and such cardiovascular disease (CVD) markers occur more frequently in patients with psoriasis. 4 Treatment of psoriasis affects the inflammation burden. Psoralen plus ultraviolet A and narrowband ultraviolet B therapies do not seem to have cardiac side effects. 4 Cyclosporine is cardioprotective against reperfusion injury after myocardial infarction, however, it can raise serum lipid levels and blood pressure. 4 Systemic retinoids can also cause severe dyslipidemia, and limited data suggest that cyclosporine and retinoids can be related to increased risk of CVD events in patients with psoriasis. 4 However, the authors 1 did not provide any information about drug usage.
These drugs may influence inflammation and arterial stiffness of the patients.
There are several types of psoriasis (eg, plaque, guttate, inverse, pustular, and erythrodermic). If the authors had mentioned the characteristics (such as stiffness index) of the subgroups of patients with psoriasis, their study would differ from other studies in the literature.
